Testing immune treatment benefit based on beta-catenin activity in liver cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies whether a liver-cancer feature called beta-catenin activity can predict who benefits from immune checkpoint inhibitor treatment. If you may not be a good candidate for surgery or local therapies, the trial may help match the right patients to this type of immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have confirmed liver cancer (hepatocellular carcinoma) and it cannot be fully treated with surgery or only local treatments, or it has come back/progressed
- You have at least one measurable tumor spot on a CT or MRI done within the last 6 weeks
- Your doctor expects you can live at least 6 months
- Your liver and kidney blood tests are within the required limits (Child-Pugh 9 or less, and other liver/kidney markers not too high)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two treatments for advanced liver cancer (hepatocellular carcinoma): a bile acid supplement called tauroursodeoxycholic acid plus an immunotherapy drug (a PD-1/PD-L1 inhibitor) that helps your immune system fight the cancer. The goal is to see if this combination is safe and effective in people who have not yet had any whole-body cancer treatment.
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests a combination of two treatments—a targeted pill (donafenib) and an immunotherapy drug (pucotenlimab)—along with a type of chemotherapy given directly to the liver through a catheter. The goal is to see if this combination can shrink or control liver cancer better than standard options.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.